EGFR and non-small cell lung carcinoma: Dramatic clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) demonstrated that these inhibitors triggered massive tumor apoptosis in NSCLC with EGFR mutation [11].